RxDoctor Payments Data

Laura Spear, APRN

Nurse Practitioner · Jacksonville, FLNPI 1760018469

Payments from drug & device makers

$2,062in general payments, 2019–2025

Across 102 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$331
  • Merck$324
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$257
  • Johnson & Johnson$211
  • Pfizer$196
  • Amgen$144
  • plus $599 from 10 others

What the payments were for

  • Food & beverage$2,062100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,062 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$2,135
Medicare patients
48
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$34,625
EntrestoSacubitril/Valsartan17$12,736
Repatha SureclickEvolocumab19$11,861
FarxigaDapagliflozin Propanediol16$9,169
Ranolazine ErRanolazine20$1,891
ClopidogrelClopidogrel Bisulfate92$1,025
Isosorbide Mononitrate ErIsosorbide Mononitrate39$731
Nitroglycerin25$696
Metoprolol Succinate60$588
Atorvastatin Calcium70$564
Rosuvastatin Calcium23$447
Amlodipine Besylate65$427
Carvedilol46$319
Ezetimibe23$247
Losartan Potassium23$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$196$34,62539 claims
NovartisEntresto$331$12,73617 claims
AstraZenecaFarxiga$47$9,16916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →